RESEARCH DOSSIER
Connected Medical Device Security Incidents and Cyber Liability Insurance
Abstract. Connected medical devices embed digital dependencies within diagnosis, therapeutic delivery, monitoring, and the organization of clinical care. Their security failures create potentially overlapping losses borne by patients, manufacturers, healthcare institutions, technology suppliers, and insurers. This monograph examines the passage from a technical vulnerability to an incident, a clinical hazard, an injury, a legal obligation, and an insured payment. It combines selected official device safety records, United States and European legal instruments, technical risk engineering documentation, peer-reviewed research on healthcare disruption and regulatory safety communications, and documented insurance wording. The analysis establishes why exposure counts, vulnerability notices, adverse-event reports, and indemnity records measure different phenomena. It examines the interaction of cyber liability, medical professional liability, product liability, technology errors and omissions, business interruption, and recall costs, with explicit attention to the actual insurance contract. Conditional numerical examples illustrate why identical expected losses can produce radically different portfolio concentration and why a common event does not necessarily correspond to one insured occurrence. The conclusion identifies evidence requirements for defensible underwriting, causation analysis, reserving, and insurance coordination. The study is a comparative documentary synthesis, not a market-frequency estimate or proposed new theory.
Keywords: Connected medical devices; medical device cybersecurity; cyber liability insurance; patient safety; cyber-physical risk; product liability; medical professional liability; cyber accumulation; insurance claims; vulnerability management.
Introduction
A connected medical device occupies several institutional positions at once. It is a physical product, a programmed instrument, a component of a clinical workflow, and frequently an endpoint of a communication system. The same alteration of its operation can generate a defective-product allegation, a failure of professional care, a privacy incident, a contractual service dispute, and interruption of a healthcare business. Risk transfer depends on the identity of the insured and the loss claimed under a particular agreement. The scientific object is therefore the relationship between technical and clinical events and the contractual distribution of their economic consequences.
Three questions organize the inquiry. First, which documented vulnerabilities and incidents establish plausible pathways to harm? Second, how do lifecycle obligations and clinical decisions influence the attribution of harm and legal liability? Third, how should coverage, exposure denominators, severity, dependence, and claims development be analyzed when multiple institutions and insurers share one technical cause?
The methodology is a structured, purposive documentary review. Primary public sources establish statutory provisions, regulator notices, and published insurance examples. Technical institutional publications describe feasible controls; peer-reviewed observational research provides context for indirect disruption. The source set is selected for mechanism and evidentiary function rather than statistical representativeness. No systematic literature-search completeness, proprietary claims access, device penetration testing, or external peer review is asserted. The analysis uses source-specific dates and jurisdictions; the insurance examples are illustrative forms, not evidence of universal clauses. Numerical scenarios are assumptions supplied by the author, not observations. The international framework is anchored in United States federal device rules, a transitional European product-liability instrument, and Canadian and Australian regulatory guidance. Cross-jurisdictional comparisons concern analytical relationships and separately specified legal instruments.
Connected Devices as Cyber-Physical Insurance Exposures
The device, its function, and its system boundary
A connected medical device in this study is a medically purposed instrument or software-mediated apparatus that exchanges information with another digital component. Connectivity includes communication with clinical systems, authorized service tools, or remote monitoring infrastructure. This research category is broader than any single statutory classification. The defining insured exposure is the capacity for a digital security event to affect data, availability, clinical decisions, or bodily integrity.
The boundary of a device must be established at four levels: its physical function; its software and firmware; the network, server, and identity services required for operation; and the human and organizational processes that convert output into care. An implanted cardiac instrument, an infusion pump, and a networked patient monitor differ in immediacy of action. A pump administers therapy; a monitor generates information that informs action; an implant may continue autonomous operation despite the loss of a remote service. These distinctions affect the causal analysis because identical network interruptions do not create identical clinical hazards.
The NIST infusion pump security architecture (2018) demonstrates an ecosystem-oriented treatment of device security. Its analytical importance lies in the inclusion of surrounding communications and server components alongside the instrument. The insurance boundary may follow a different line: an endpoint can be clinically important while falling outside the definition of a covered computer system. Conversely, a hospital server may qualify as insured infrastructure even if its dependence on an individual device is indirect.
The insurance relevance of connectivity varies by control. A hospital may administer network credentials without controlling the device's signed firmware. A manufacturer may authorize an update without determining its safe installation time on a ward. A service provider may control remote access without knowing the patient's physiological condition. Evidence must identify which actor could have changed the outcome at each point. A purchase invoice establishes acquisition; an asset register establishes recorded inventory; neither alone establishes operational control of all digital dependencies.
Distinct event and loss categories
The following terms are operational definitions used for this inquiry. A vulnerability is a weakness capable of enabling an adverse security action. An exploit is an action or mechanism that takes advantage of a weakness. A security incident is an event that actually or credibly compromises security under the applicable technical or legal definition. A clinical hazard is a potential source of harm under particular use conditions. Injury is the realized harm suffered by a patient, while legal liability is an obligation established by applicable law or accepted through settlement. A covered claim is a demand or loss meeting a policy definition and insuring agreement, subject to conditions and exclusions.
The transition from one category to another is contingent. A vulnerability can prompt a recall without injury. A compromised network can interrupt monitoring without compromising the firmware of a single device. A patient can deteriorate during a cyber incident from an unrelated disease. A legally actionable injury can fall outside a particular policy, and covered response expenses can be incurred in the absence of a third-party injury claim.
| Observation | Evidence sought | Distinct insurance question |
|---|---|---|
| Vulnerability | Affected version, configuration, disclosure | Does a preventive expense trigger exist? |
| Security incident | Logs, forensic findings, access and timing | Does the event meet the policy definition? |
| Functional disruption | Alarm, treatment, or availability records | Was insured business or clinical service impaired? |
| Patient injury | Clinical records and causal assessment | Which liability agreement may respond? |
| Demand or suit | Pleadings, notice, jurisdiction, damages | Which insured and trigger attach? |
| Settlement or payment | Allocation, limits, retention, recoveries | What is indemnifiable and by whom? |
The table is a classification aid. An insurer may have an obligation to defend an allegation before the injury's cause is established. A regulator may require a field correction while no insurance claim exists. Distinct statuses should be retained in a common incident record instead of being condensed to a binary indicator of insured loss.
Economics of the connected ecosystem
The central economic trade-off is between clinical productivity from interconnection and new contingent loss pathways. Integration can reduce work duplication and facilitate monitoring. It also transfers some reliability requirements from the local instrument to shared services. The exposure increases when a service has limited substitutes, when downtime tolerance is short, and when many devices depend on one supplier.
The relevant counterfactual is the performance of the same clinical service under a feasible alternative architecture, not the assumption that a disconnected technology is always safe. Connectivity may support safety updates, remote expertise, and earlier detection of deterioration. Insurers need information on both the function enabled by connectivity and the consequence of its failure. A disconnected fallback that eliminates a critical monitoring service can itself create a new hazard.
Risk ownership follows the contract, regulation, and actual capacity to control risk. The purchaser has incentives to minimize acquisition cost, the manufacturer to sustain product viability, and the healthcare institution to maintain continuity. When one party bears the cost of a safety improvement and another receives the reduction in expected insured loss, coordination of incentives can be weak. Procurement terms, support commitments, risk engineering, deductibles, and coverage conditions can influence each party's decision without guaranteeing a particular clinical outcome.
Vulnerabilities, Incident Evidence, and Clinical Causation
Documented device safety cases
In the MiniMed insulin pump recall, the FDA (2019) documented a corrective action associated with possible unauthorized wireless adjustment of insulin delivery, with subsequent renotification in 2023. The record provides evidence about a design vulnerability and a response. It cannot be treated as verified evidence of an attack involving a patient or proof that any insurer paid for corrective measures.
This distinction has immediate analytical consequences. A manufacturer may face costs for notices, replacements, field service, or engineering changes. Patients may incur additional visits, and providers may need to coordinate alternative treatment. Whether these expenses fall on product recall insurance, a contractual warranty, self-insurance, or a cyber policy requires separate verification. The recall supplies evidence of a risk-management obligation, not of a covered loss amount.
The Contec and Epsimed safety communication of January 2025 described risks involving patient monitors connected to the internet. FDA identified possible disruption or manipulation of device operation and unauthorized transmission of patient information. At the time, the agency reported no known associated security incidents, injuries, or deaths. Its July 2025 update announced availability of a software correction. These facts support analysis of a potentially multi-device exposure and the difference between a disclosure, a preventive response, and injury evidence.
A monitor's ordinary output enters a clinical judgment process. Incorrect values may lead to a false interpretation, whereas an unavailable monitor may create delayed observation. The clinical risk is conditional on the physiological state, availability of other observations, personnel response, and the interval between error and intervention. The same technical issue could generate materially different injury distributions across intensive care, routine observation, and home monitoring.
| Case | Verified evidence | What remains unestablished |
|---|---|---|
| MiniMed recall | Possible unauthorized change to insulin delivery; correction communication | Number of realized attacks, patient injuries, insured payments |
| Contec/Epsimed notice | Potential control, availability and privacy exposure; subsequent patch | Later injury incidence or claim distributions |
| Regional ransomware study | Measured changes in neighboring hospital operations | Compromise of a particular connected medical device |
What published safety communications measure
Menon (2026), in a systematic qualitative content analysis, identified 18 FDA cybersecurity safety communications dated between June 2013 and January 2025, of which approximately 94 percent fell into the author's high-risk classification. The result describes the selected regulatory communication material. The unit is the communication, not a device, exploited vulnerability, injured person, or insured claim. Table 1 contains alerts involving particular products alongside alerts about widely shared components. A single component alert can implicate numerous models, while one model can be the subject of multiple communications. These observation structures make a simple count unsuitable for actuarial frequency estimation.
A second source supplies a deliberately different observation perspective. In its 2023 medical device cybersecurity review, GAO reported that the available hospital incident information described by HHS did not identify weaknesses in devices as common attack entry points. GAO also interviewed 25 selected external entities, including organizations representing patients, providers, and manufacturers. These findings are consistent with a category of potentially serious loss whose actual occurrence is difficult to estimate. They do not establish a universal low frequency or prove a lack of harm.
The two studies answer different questions and should not be pooled. Safety authorities may give priority to credible threats with severe possible outcomes before exploitation occurs. Hospital incident records identify observable operational security failures, subject to organizational detection and classification. There is also an important asymmetry between a device that initiates network compromise and a downstream device that becomes unavailable when the hospital network fails. Recording only initiation will systematically miss some device-dependent clinical consequences.
An insurer can learn about vulnerability classes and potential accumulation channels from these publications without adopting their counts as historical claim observations. A defensible underwriting estimate would additionally identify deployed units, network contexts, device-years of observation, attack detection practices and insured exposures. Even the same high-risk classification may represent dissimilar probability distributions when one facility isolates a vulnerable device and another exposes the same device to unmanaged connectivity.
From digital failure to bodily harm
An injury analysis requires a chronology connecting the compromised system to the patient's clinical course. Four questions are especially important: what function was disrupted; which patient was exposed to the disruption; what intervention would ordinarily have been possible; and what outcome would plausibly have occurred with the alternative intervention. A technical chronology establishes opportunity and mechanisms; medical evidence establishes compatibility of the proposed mechanism with the outcome.
The temporal sequence may be reconstructed from device telemetry, firmware version, service records, network logs, orders, administration timestamps, observations, and staff reports. Corroboration between independent sources is stronger than an unverified export from the system suspected of compromise. Clock offsets, incomplete network retention, undocumented manual actions, and compromised log integrity can all introduce uncertainty.
Consider a hypothetical infusion incident. A network access allegation is followed by an unexpected programmed dose and an adverse reaction. A causal investigation must evaluate the prescribed dose, the actual delivery, device calibration, foreseeable human programming mistakes, medication identity, patient susceptibility, and whether the claimed compromise could have produced the observed change. It must establish evidence of the attack rather than simply matching a known vulnerability to a later injury. An alternative causal explanation may be supported by records even where network security was deficient.
A separate availability pathway occurs when the instrument behaves normally but supporting infrastructure fails. Clinicians may have to use temporary records, alternate devices, or manual checks. Patients may be transferred. Delays can propagate beyond the original insured premises. Legal causation in a particular case depends on the applicable standard, individualized injury evidence, and institutional duties. Clinical plausibility and legal attribution therefore require distinct assessments.
Regional disruption as indirect exposure
Dameff and colleagues (2023) examined the effects of a month-long ransomware attack at a healthcare organization on two neighboring emergency departments. Their observational emergency department study reports 6,114 visits before the attack, 7,039 during attack and recovery, and 6,704 afterward. The daily mean census rose from 218.4 to 251.4, and median door-to-room waiting time increased from 21 to 31 minutes during the attack phase.
These are measured associations in specified hospitals and time windows. They supply empirical evidence that the impact of digital disruption can extend beyond a targeted institution. The study does not establish that a device was compromised or that a particular delay caused compensable harm. It also does not establish how insurance contracts responded.
For connected-device risk, the implication is conditional: whenever clinically important capacity depends on digital services, interruption may produce indirect loss through displaced care. Modeling only the number of disabled devices can overlook the institutional consequence of transfers, queues, unavailable replacement capacity, and increased workload elsewhere. The impact should be analyzed as a health-service dependency as well as a digital-asset failure.
Lifecycle Security, Regulatory Duties, and Patient Harm
United States device regulation
The statutory basis for United States cyber-device submission requirements is section 524B of the FD&C Act (enacted 2022). A device meeting the statute's software, internet-capability, and vulnerability criteria is subject to the specified submission provisions. Requirements include a plan for postmarket vulnerabilities, processes supporting reasonable cybersecurity assurance, appropriately timed updates, and a software component inventory. Exemptions are contemplated by the statute. The provision is not a blanket retroactive requirement imposed identically on all network-connected objects.
The FDA's February 2026 premarket guidance addresses cybersecurity design, labeling, submission documentation, and section 524B, replacing the June 2025 guidance. Guidance recommendations and statutory requirements have different legal functions. An insurer's review should distinguish evidence of compliance with an applicable requirement from evidence that a recommendation was followed and from evidence that a control actually performed under operational conditions.
Device clearance or approval is evidence of a regulatory process, not a guarantee of continuous invulnerability. Software supply and the conditions of use change across a device's lifecycle. Procurement should therefore identify the period for which updates are supported, whether the vendor can notify the operator about newly discovered weaknesses, and the practical method for safe replacement of a device whose security is no longer supportable.
European product liability during transition
The revised European Product Liability Directive (2024) expressly includes software within the product category and incorporates cybersecurity-related safety considerations into defect assessment. It establishes a future-facing legal structure for software-mediated products and the relationship between continuing manufacturer control and product safety.
Temporal scope matters. Article 2(1), as corrected by the May 7, 2026 corrigendum, applies the new directive to products placed on the market or put into service after December 8, 2026. Articles 21 and 22 set the repeal transition and national transposition deadline. For earlier products, applicable prior liability rules and national law must be assessed; this manuscript does not infer that the new directive already governs a November 2026 injury. National implementation and the precise facts of subsequent modifications require jurisdiction-specific investigation.
The insurance implication is clear even during the transition: a manufacturer that supplies software as part of ongoing product performance has an exposure that cannot be assessed solely by physical condition at initial delivery. The applicable legal basis, date of placement or service, manufacturer control, and insurance trigger are separate inquiries. No regulatory classification by itself determines a policy's product definition or the amount payable.
Canadian and Australian regulatory perspectives
Health Canada's (2019) premarket cybersecurity guidance treats security as a contributor to the safety and effectiveness of software-containing medical devices. Its design, risk management, verification and planning recommendations address all four device classes, while the licensing submission discussion focuses on classes III and IV. The foreword identifies guidance as an administrative instrument without independent legal force. The correct insurance interpretation is therefore to examine what safety and regulatory obligations govern the particular device, what evidence the guidance recommends, and what demonstrable deviation is relevant to an alleged loss. A guidance document may inform an expert assessment without settling the governing legal standard.
Australia's Therapeutic Goods Administration (TGA, 2025) addresses security through its total product lifecycle guidance. It connects premarket design, ongoing risk control, and product obsolescence, and describes distinct evidentiary responsibilities for manufacturers and sponsors. The guidance notes the problem of clinical service lives exceeding the supported lifetime of embedded computing technology. It also treats vulnerability updates and security measures as part of the broader safety and performance framework.
These regulatory perspectives reinforce the importance of distinguishing hardware longevity from the period during which embedded programs and dependencies can be maintained safely. Insurance exposure follows the installed and supported population, not an invoice history alone. Suppose a hypothetical manufacturer sells a device with a ten-year expected clinical service life and a five-year support commitment. For underwriting purposes, the duration of residual deployment after support expiration matters as much as the initial volume sold. A replacement contract or upgrade capability can shorten the exposure period; continuing operation in an unsupported configuration may extend it.
A comparative assessment should keep legal jurisdictions separate. The United States statutory submission requirement for cyber devices, Canadian guidance and Australian essential-principles framework use different regulatory structures. The EU product liability transition likewise operates on its own temporal basis. An insurer may adopt compatible evidence requirements for these territories, but a common underwriting questionnaire cannot establish that compliance, defect, negligence, and claim admissibility have identical legal meanings everywhere.
Local policy and global program structures add a distinct contractual dimension. A single device model may be distributed through different legal entities and different insurance programs. A recall expenditure made by a parent manufacturer can differ from a personal injury demand against a local distributor; an interruption at a healthcare provider can be governed by an entirely separate insurance contract. Jurisdiction, distribution chain, insured status, operative wording and the contractual period should all be retained as separate claim-allocation fields.
Health information and organizational responsibilities
In the United States, the HIPAA Breach Notification Rule describes obligations associated with breaches of unsecured protected health information by regulated covered entities and business associates. A confidentiality incident can therefore generate investigative and notification costs independently of physical injury. The scope turns on the regulated actor, the information, the event, and the rule's conditions.
An Internet-connected device can transmit clinically important data while a vendor operates a platform outside a hospital's directly administered systems. Establishing who collected, stored, transmitted, or accessed the data is necessary for identifying legal and contractual responsibilities. The device manufacturer may act in different roles under different service arrangements. The analysis cannot assume every consumer health application or device manufacturer is a HIPAA covered entity or business associate.
Responsibility also includes the capacity to provide safe care during remediation. A software correction may require temporary interruption or verification. If a clinically essential instrument cannot be safely substituted, a remediation plan must account for this constraint rather than treating software installation as a routine administrative task. Relevant evidence includes the vendor notice, the site's affected inventory, compensating controls, installation scheduling, clinical approval, and post-installation verification.
Legacy devices and operational controls
The legacy device cybersecurity report summary (2023) identifies shared lifecycle responsibility, vulnerability management, training, and mutual aid as relevant considerations, including for less-resourced healthcare organizations. Its institutional nature is important: it identifies implementation challenges rather than estimating their insured frequency.
Aging equipment can remain mechanically functional while software support becomes inadequate. Replacing all affected instruments immediately may be economically impossible or may temporarily reduce clinical capacity. An insurer should assess the actual supported lifetime of a device, clinical substitution options, network separation, monitoring capability, and a realistic transition plan. A supported device is not automatically low risk; an unsupported device with a carefully controlled use environment may have a materially different exposure from the same model with uncontrolled external access.
Security controls should be evaluated by their effect on the relevant loss pathways. An asset inventory helps identify affected populations; an authorized access process reduces opportunities for misuse; network separation can limit propagation; recovery testing establishes whether planned recovery is feasible. The infusion pump implementation example demonstrates the relevance of controls that encompass the device and surrounding infrastructure. It does not provide an empirical percentage reduction in claims for a particular insurer.
For a clinician, a security control has to preserve safe use. For an insurer, control verification should establish actual coverage of the relevant device population, not merely an organization-wide declaration of adoption. For a manufacturer, an update process should enable identification of the installed versions and evidence of delivery and safe deployment. The interaction of these three requirements determines whether a control can reasonably reduce both the probability and severity of loss.
Insurance Contract Architecture and Liability Coordination
The allocation of insured interests
Cyber insurance may transfer first-party response expenses, data restoration costs, business interruption, and specified third-party security or privacy liability. Medical professional liability addresses liabilities arising out of insured professional activities. Product liability addresses legal responsibility for harm attributed to an insured product. Technology errors and omissions insurance addresses specified liability from technology products or services. Recall coverage may reimburse specified withdrawal costs. Each description identifies a candidate insuring interest rather than a guarantee of coverage.
An injured person is not necessarily the insured under the hospital's cyber contract. First-party expenses are ordinarily incurred by the insured entity itself, whereas third-party liability concerns amounts for which the insured is legally responsible or which qualify for defense. Health insurance may finance clinical treatment following injury, subject to its own terms and applicable recovery rules. This payment does not resolve the provider's or manufacturer's legal liability.
| Loss component | Candidate responding coverage | Contract issue |
|---|---|---|
| Forensic and response costs | Cyber first-party | Covered event, consent, sublimit |
| Lost clinical revenue and extra expense | Cyber business interruption | Trigger, waiting period, restoration period |
| Unauthorized health data disclosure | Cyber privacy liability | Insured data, insured actor, exclusions |
| Alleged injury from defective device | Product liability | Product definition, occurrence, aggregation |
| Alleged failure to provide appropriate care | Medical professional liability | Professional services, claim date, exclusions |
| Platform service failure | Technology E&O | Covered service, economic loss, liability exclusion |
| Preventive device withdrawal | Recall insurance | Recall trigger, covered expense, territorial scope |
The table does not establish a priority rule. In particular, physical harm may be covered or excluded depending on the wording of individual cyber, casualty, and professional policies.
Bodily injury exclusions and affirmative write-backs
A documented example of contractual separation is the CyberEdge specimen wording (AIG, 2013). The specimen's security and privacy coverage section, form 101024, contains a bodily injury/property damage exclusion in subparagraph (d) on page 5. This historical example shows why proving a cyber security failure does not alone establish coverage for an associated bodily injury. The exact executed insurance policy, including later amendments, remains controlling.
The Lloyd's Market Association's 2021 cyber clause bulletin identifies a full cyber exclusion and multiple limited versions for liability forms. The limited versions differ in the categories of injury restored and the event definitions used. Some distinguish bodily injury from mental injury. This primary industry documentation establishes the existence of materially different drafting alternatives, not their frequency of use.
Two opposing assumptions are equally hazardous: that all cyber-caused injury is covered by cyber insurance, and that all physical injury will necessarily be picked up by casualty insurance. A gap can arise when the cyber policy excludes injury and the liability policy excludes a cyber-related cause. An overlap can arise where one contract affirmatively writes back cyber-caused bodily injury while another covers a defect or professional service. Both outcomes depend on actual contractual language.
Coverage analysis must examine the sequence of the insuring agreement, definitions, exclusions, exceptions, endorsements, conditions, limits, and applicable legal interpretation. The exception to an exclusion generally has to be considered within the rest of the policy. It cannot safely be treated as unlimited affirmative coverage independent of the underlying grant.
Comparison of actual exclusion architecture
The reproduced LMA5475B endorsement dated July 23, 2021, appears in a publicly hosted 2024 volunteers insurance liability contract. It supplies a useful nonmedical example of how terms can partition cyber-related losses. Paragraph 1 establishes a broad exclusion for cyber acts or incidents, data breaches and specified forms of electronic data loss. Paragraph 2 preserves an exception for qualifying bodily injury and property damage related to the specified events, with express restrictions on mental injury and a reservation concerning remediation costs. Paragraph 3 separately lists data-breach expenditures outside coverage. Its definitions distinguish an unauthorized or malicious act from operational errors or failures, and restrict property damage to injury to tangible property and associated loss of use.
These provisions demonstrate why a write-back must be read with the underlying liability grant, definitions and restrictions. The exception does not independently insure a device manufacturer's liability: the particular contract is for a different insured population. Nor does it automatically compensate a hospital for technical remediation or patient notification. The example nevertheless permits a direct comparison with an exclusion in the AIG cyber specimen described above. Their interaction, if comparable provisions were used in a hypothetical coordinated program, could leave bodily injury for a liability contract while placing response expenditure under a cyber policy. This conditional statement presupposes the relevant insuring grants, classifications, conditions and exclusions. Actual program terms are not represented by the two documents.
Consider the following distinction. A manipulation of device settings that causes a patient's injury potentially falls within liability wording that preserves claims concerning bodily injury. A hospital's cost to verify, restore and replace firmware can be economically attributable to the same event but treated differently under an exclusion for loss of electronic data or remediation. A demand for psychological harm alone can raise a further definitional issue. A component with damaged physical circuitry and a functioning component with corrupted data are also distinct interests under wording that restricts property damage to tangible property.
General liability coverage alone cannot therefore be inferred from the physical nature of an adverse clinical outcome. The specific insured, business activity, medical or product exclusions, claim timing and applicable law determine the actual outcome. In particular, the presence of an exception in a general liability policy does not demonstrate its presence in the professional liability or excess layer. A full coverage review compares all layers and endorsements; this monograph examines public forms for their interpretive structure and does not claim to reproduce a live medical enterprise program.
For a hypothetical hospital and manufacturer, a contract-comparison worksheet should separately record:
| Contract element | Required factual or contractual evidence |
|---|---|
| Named insured and insured capacity | Which legal entity supplied, integrated or operated the device? |
| Harm and interest | Which claimant suffered injury, data loss or interruption? |
| Grant and temporal trigger | What event and claim dates satisfy the relevant policy? |
| Cyber exclusion and exception | Which categories of harm and causes are excluded or preserved? |
| Professional and product exclusions | Do other terms remove a claim within the initial grant? |
| Expense wording | Do restoration, investigation, recall or litigation costs qualify separately? |
| Excess and reinsurance interface | Do higher layers adopt the relevant definitions and exclusions? |
The worksheet is an analytical aid derived from the compared wording, not a new coverage model or an assertion that insurers are obliged to use these fields.
Time, multiple claims, and defense
For an implanted device, software design can precede installation by years; the incident may occur during a later renewal period; injury may be detected subsequently; and the patient may file suit still later. The relevant insurance trigger can fall at different points for different contracts. An occurrence-based grant and a claims-made grant should be assessed using their own definitions, retroactive dates, reporting requirements, and policy periods.
Consider three claims involving devices with the same component. One allegation concerns failure to correct a vulnerability; another concerns unsafe deployment of a patch; a third concerns disclosure of health data. The common component is evidence of technical dependence but does not determine whether the claims are related for insurance purposes. The contract may focus on acts, occurrences, common causes, or series of related events. Different definitions may create different allocations across years or limits.
Defense costs also differ from indemnity. A claim can require legal defense even where causation is disputed or the insured ultimately owes no damages. One policy may treat defense expenses within the liability limit, another may provide separate treatment. A combined settlement may include compensation, claimant expenses, investigation costs, and other items with distinct coverage statuses.
Notification is a separate problem from coverage. Incident response records may need to be preserved and potential insurers identified before parties can determine their final liabilities. Contractual deadlines, consent requirements, and cooperation provisions must be assessed under each agreement. Communications with insurers should distinguish established facts from hypotheses, because premature attribution may distort later coverage and subrogation investigations.
Coordination and the economics of allocation
Assume hypothetically that one event causes a hospital $400,000 in response expenses, $600,000 in lost contribution margin and extra expense, and a $2 million bodily injury settlement. These are distinct, mutually exclusive economic components in the example, totaling $3 million before insurance. Suppose the cyber policy covers the $1 million first-party loss with a $100,000 retention and a $750,000 applicable limit. Its payment is $750,000. Suppose a separate liability policy covers the settlement with a $250,000 retention and a $1.5 million applicable limit. Its payment is $1.5 million. Total insurer payment is $2.25 million and the residual is $750,000. This arithmetic assumes all terms, approvals, triggers, and allocations stated in the example; it assumes defense costs are absent.
If both liability policies instead exclude the relevant cyber-related injury, the $1.5 million hypothetical liability payment disappears. The residual increases to $2.25 million. If only part of the interruption loss qualifies, cyber indemnity must be recalculated. The example demonstrates why pricing an assumed loss type and pricing the actual contractual obligation are different tasks.
Contractual indemnities between a manufacturer and hospital may shift an economic burden, but an insurance contract may treat assumed contractual liability differently from independently existing legal liability. Additional-insured provisions, their scope, other-insurance provisions, waiver of subrogation, territorial clauses, and the legal enforceability of indemnity promises require individual analysis. Recovery from another party should not be counted twice or assumed collectible at full value.
Actuarial Measurement, Dependence, and Claims Development
Exposure denominators and observation processes
A meaningful rate has a defined numerator and denominator measured for a consistent population and interval. Vulnerabilities per product version, attacks per exposed device-month, injuries per patient-device episode, liability claims per provider-year, and insured payments per policy-year answer different questions. Device counts can help describe exposure, but the number of installed devices is not necessarily the number connected to a vulnerable network or the number in clinical use.
The FDA's MAUDE reporting limitations explicitly caution against using passive medical device reports alone to estimate event rates or causality. The underlying problem is missing exposure denominators, incomplete and imperfect reporting, and uncertain attribution. An increase in published notices may reflect stronger research, detection, or disclosure rather than a comparable increase in underlying exploitation.
A linked research dataset would require installed model and version, dates of operation, configuration exposure, support status, incident history, patient-use denominators, claim and policy identifiers, gross loss, insurer payments, and ultimate development. Sensitive clinical information should be minimized and appropriately protected. Entity resolution is necessary because the same incident may be reported at device, hospital, regulatory, and insurance levels.
Selection is endogenous. Organizations with stronger monitoring may discover more incidents while experiencing fewer severe consequences. Organizations purchasing insurance may hold different risk profiles from uninsured institutions. Claims databases are filtered by contract wording, reporting incentives, deductibles, and coverage outcomes. A raw correlation between control use and reported incident count cannot identify the causal effect of the control on loss.
Linking device and claim observation systems
In its 2024 postmarket surveillance review, GAO identified incomplete integration of unique device identifiers into clinical documentation and billing claims as one of the impediments to active regulatory surveillance. This limitation is significant for insurance research because linked observations are needed to isolate the medical products used in a particular clinical encounter. For a security-oriented study, even a consistently used product identifier would still need to be supplemented by version, relevant component and configuration histories; it identifies the product rather than necessarily its software state at the time of an event.
An actuarial dataset should preserve the separate times of exposure, detection, loss manifestation and insurance reporting. For each linked incident and claim, an analyst would need at least the covered entity, installed device group, exposure duration, security or operating failure category, evidence of harm, allocation status, reporting date, payment date, amounts and policy terms. In a multi-insurer event, a common technical identifier can help prevent multiple descriptions of the same event from being treated as independent observations. It should not be used to collapse genuinely different claims into a single contract-defined occurrence.
The absence of linked records creates both denominator and numerator uncertainty. A vulnerability may affect a device population that cannot be completely enumerated. Even where a complete inventory exists, operations logs may be insufficient to distinguish attempted exploitation from successful intrusion. An interruption may be recorded without a device-specific causal label, and a clinical record may identify delayed treatment without a cyber incident identifier. A disputed liability demand may remain unresolved for years. Estimates of reported claims frequency can therefore change because of linkage and ascertainment, independently of actual changes in safety.
A prospective multicenter study could specify facility and device-years in advance, maintain version-specific inventories, record independent incident evidence, classify operational and clinical outcomes, and follow claims to settlement or censoring. The method should distinguish shared technical events from independent events and account for unequal observation lengths. Researchers would report missing-link rates, detection assumptions, and the sensitivity of estimates to alternative attribution rules. Only then could the study assess whether the additional uncertainty justified a formal measurement error adjustment. Available public sources do not provide such a joined dataset.
Conditional frequency and severity
Let N represent the number of relevant events during a period. Let X_j denote the gross loss associated with event j and Y_j the insured indemnity under a specified policy. The expected aggregate insured indemnity is E[sum Y_j]. Under independent and identically distributed severities independent of event count, this reduces to E[N] E[Y]. The reduction is convenient but depends on assumptions that may fail in a portfolio of common device platforms.
A single fixed per-event deductible d and limit u imply the simplified payment Y = min(u, max(X - d, 0)). Annual aggregate limits, claims-made reporting, defense treatment, multiple coverage grants, sublimits, and exclusions need their own representation. Deductibles and limits apply to the contractually defined unit of loss, and that unit need not coincide with each patient injury.
For a synthetic exposure of 10,000 device-years with assumed incident probability 0.002 per device-year, the expected incident count is 20. If 5% of incidents cause injury and 40% of those injuries lead to a covered liability claim, the expected count is 0.4 covered liability claims. With a conditional mean paid indemnity of $500,000, expected liability indemnity is $200,000. This assumes a single relevant incident per device-year, a homogeneous population, and sufficient limits. It excludes defense, first-party costs, and premium loadings.
Increasing injury probability to 10% multiplies expected liability indemnity to $400,000. Reducing covered-claim conversion to 20% returns it to $200,000 with the higher injury probability. These transparent stress inputs show that a stable insured loss cost can conceal materially different underlying clinical risk and policy penetration. They do not estimate actual rates from the two device notices.
Common dependencies and accumulation
The direction of dependence matters for risk capital. Consider 100 insured institutions, each with a marginal 1% annual probability of a $1 million covered event. Ignoring expense and policy aggregates, expected annual loss is $1 million under either independence or perfect positive dependence. Under independence, the count has binomial variance 100 times 0.01 times 0.99 = 0.99; the aggregate standard deviation is approximately $0.995 million. Under a common event that hits every institution together with 1% probability, annual loss is $100 million with probability 0.01 and zero otherwise. Its standard deviation is approximately $9.95 million. The mean is unchanged while the standard deviation increases by a factor of ten.
A connected medical device portfolio may contain shared product versions, software components, remote maintenance systems, authentication services, or data platforms. Dependence can arise even if organizations have no contractual relationship with one another. The Contec notice is relevant as an example of shared vulnerability potential; it does not quantify the probability of simultaneous exploitation.
An accumulation assessment should separate common software exposure, exposure to a single attack, actual business and clinical disruption, individual policy responses, and contractual aggregation. A software flaw may affect many versions differently. A common cloud outage may interrupt several insureds but fall outside some dependent-interruption definitions. A single technical event may produce multiple policy occurrences, or several technical events may be linked by a related-claims provision.
Scenario design should vary the affected population, exploitation reach, downtime distribution, clinical substitution capacity, injury severity, contract treatment, and recoveries. A severe scenario must distinguish a worst credible joint loss from an expected annual loss. Neither number is established by the count of published vulnerabilities.
Claims development and reserving
Connected-device losses can produce different reporting and settlement lags. Forensic invoices and emergency interruption expenses may become observable relatively early. Injury allegations can arise after medical outcomes become clearer. Product liability litigation, allocation between defendants, and recoveries may develop across a much longer period. A study of financial performance should distinguish payments made, outstanding estimates, and the ultimate expected obligation.
A claim record should preserve the originating incident and the coverage-specific component. Where data permit, development should be examined by first-party response, property damage, bodily injury, privacy liability, and defense, rather than assuming one development pattern for all cyber exposure. Sparse credible data warrant explicit sensitivity testing rather than mechanically transferring development factors from another class.
Reinsurance can mitigate concentration, provided the treaty actually covers the relevant underlying risks and defines event, attachment, and limits appropriately. The underlying insurer's technical classification and reinsurance recoverability are independent questions. If individual policies respond to physical injury but a treaty excludes cyber origin, gross and net exposures can diverge materially. A portfolio review should therefore trace the conditions of reinsurance rather than deducting estimated recoveries without evidence.
Integrated Scientific Synthesis and Research Agenda
Claims coordination as an evidentiary process
A practical claim investigation can start with a time-stamped chronology common to all potential responders. It should then branch into the technical facts, clinical facts, each insured party's obligations, each legal demand, and each policy response. The original event identifier remains useful for understanding common dependence, while claim identifiers remain necessary for legal and contractual distinctions.
The authorial synthesis is that cyber-physical insurance loss is mediated through an institutional sequence. Technical exposure establishes an opportunity for loss; care processes determine the consequence for patients; legal relationships determine who owes compensation; and policy terms determine what portion of that obligation is transferred. These relationships draw on conventional causal and insurance analysis. They are not a new named theory.
A hospital with high cybersecurity maturity may still be exposed to the failure of a manufacturer-supported service, while a manufacturer with secure product design may encounter unsafe deployment configurations. A policyholder's security assessment must consequently incorporate dependencies and the boundaries of its actual control. A risk improvement requirement should be assessed for feasibility, verifiability, and clinical consequences.
The distinction between preventive expenses and injury compensation is equally important. Where a vulnerability is identified before an exploit, actions to reduce risk may be socially and economically valuable even if no insurance trigger has attached. Insurance coverage for those expenditures requires a contractual basis. The absence of indemnity does not establish that prevention lacks value, and the existence of coverage does not by itself establish that the chosen remediation is clinically sound.
Research priorities and falsifiable empirical questions
Future empirical work should link longitudinal device inventories, version-specific exposure, incident detection, clinical process data, and claims records. It should define the unit of observation before assembling the data and evaluate linked records for reporting and duplication bias. An observed association between device age and losses should be tested against support status, clinical criticality, exposure environment, and procurement differences.
One useful comparison would examine institutions with comparable device populations and differing verified access separation or recovery capabilities. Outcomes could include attack propagation, duration of functional interruption, disruption of care, and covered loss severity. Confounders would include institutional resources, staffing, the clinical complexity of cases, and detection maturity. A causal design should specify what intervention changed and how comparison institutions were selected.
A second question concerns policy design. Matched historical claims could be adjudicated under alternative, clearly specified coverage wordings to examine the sensitivity of indemnity to bodily injury exclusions, related-claim clauses, and defense-cost arrangements. Such exercises would estimate contractual sensitivity under a defined sample rather than establish market-wide coverage rates.
A third question concerns shared dependencies across manufacturers and providers. An exposure register could trace common software or service components to affected device versions and operational sites. Researchers could assess the joint effect of dependency concentration and limited substitutes on economic losses. Insurer and reinsurer claims datasets would be required for empirical calibration of financial tails.
Limitations and scientific boundaries
This research examines selected, verified documentary cases, not a complete catalogue of security incidents. The FDA examples provide vulnerability and corrective-action evidence, not a census of exploited devices. The regional ransomware study concerns hospital disruption rather than device-level attacks. The technical security documentation illustrates controls, without measured insurance effectiveness. The AIG sample form and LMA bulletin demonstrate contractual alternatives without establishing the current distribution of clauses or the treatment of any actual claim.
The legal comparison is deliberately bounded to specific instruments; this study does not determine the law of every country or every United States state. The European liability directive's transitional scope is stated explicitly. No confidential clinical records, policy schedules, claim files, reinsurance treaties, or market-level device-loss microdata were obtained. No real claim frequency, expected market indemnity, premium, or reserve is estimated. The hypothetical calculations are reproducible analyses of stated assumptions.
The boundaries matter because an apparently precise but unsupported estimate of patient injury from cyber incidents would distort underwriting and public understanding. A study can explain documented mechanisms and contractual relationships with substantial confidence while leaving empirical prevalence and causal effects unresolved. Those remaining questions require suitably designed data collection.
Conclusion
Connected medical device security incidents create insurance exposures through the intersection of digital systems, clinical services, products, and legal obligations. A documented vulnerability establishes a technical risk; evidence of an actual security event, clinical consequences, and applicable legal responsibility is required for a substantiated injury claim. Coverage then depends on the agreement governing the particular insured and loss.
The documentary cases illustrate the value of correcting security vulnerabilities before an observed injury, while observational healthcare research establishes that digital disruption may affect organizations beyond the original target. These findings justify a wider examination of clinical capacity and common dependencies without supporting a numerical estimate of device-related injury incidence.
The comparison of legal requirements and insurance examples establishes the importance of lifecycle responsibility and explicit cyber-physical coverage analysis. Product, clinical professional, cyber, technology, and recall exposures can coexist. Exclusions and write-backs may produce gaps or overlap; the only defensible resolution is contract-specific interpretation supported by the factual record.
For actuarial science, the essential tasks are consistent denominators, event and claim linkage, explicit contract modeling, separate claims development, and concentration analysis. The numerical illustrations demonstrate the effect of conditional injury and claim conversion probabilities and the effect of dependence on portfolio variability. Empirical calibration remains an independent task. A reliable insurance assessment integrates the technical conditions of safety with the clinical, legal, and economic conditions under which losses are realized and transferred.
References
AIG, Inc. (2013). CyberEdge sample specimen form, Security and Privacy Coverage Section, form 101024 (12/13), p. 5 of 8, exclusion (d). Original source
Dameff, C., Tully, J., Chan, T. C., Castillo, E. M., Savage, S., Maysent, P., Hemmen, T. M., Clay, B. J., & Longhurst, C. A. (2023). Ransomware attack associated with disruptions at adjacent emergency departments in the US. JAMA Network Open, 6(5), e2312270. doi:10.1001/jamanetworkopen.2023.12270. Original source
European Parliament & Council of the European Union. (2024). Directive (EU) 2024/2853 of 23 October 2024 on liability for defective products and repealing Council Directive 85/374/EEC. Official Journal of the European Union, L, 2024/2853. Original source
European Union. (2026, May 7). Corrigendum to Directive (EU) 2024/2853 on liability for defective products. Official Journal of the European Union, L 2026/90364. Original source
Food and Drug Administration. (2019). Class 2 device recall: MiniMed insulin pump. Medical device recall database, record 175194; subsequent correction recorded January 2023. Original source
Food and Drug Administration. (2025, January 30; updated July 2). Cybersecurity vulnerabilities with certain patient monitors from Contec and Epsimed: FDA safety communication. Original source
Food and Drug Administration. (2026, February). Cybersecurity in medical devices: Quality management system considerations and content of premarket submissions. Final guidance, docket FDA-2021-D-1158. Original source
Food and Drug Administration. (n.d.). About Manufacturer and User Facility Device Experience (MAUDE) database. Retrieved November 18, 2026. Original source
Health Canada. (2019). Guidance document: Pre-market requirements for medical device cybersecurity. Adopted June 17, 2019; effective June 26, 2019. Original source
Lloyd's Market Association. (2021, July 23). Cyber and Data Limited Exclusion Endorsement 2 (LMA5475B), reproduced in the 2024 Volunteers Insurance Service liability policy, hosted by Ohio State University Extension. Original source
Lloyd's Market Association. (2021, July 29). Updated cyber clauses for use on US GL and excess liability coverage forms. Bulletin LMA21-032-TE. Original source
Menon, V. (2026). Cybersecurity breaches in medical devices: Analyzing FDA safety communications in response to patient security concerns. Frontiers in Digital Health, 8, 1701551. doi:10.3389/fdgth.2026.1701551. Original source
MITRE. (2023, November 15). Next steps toward managing legacy medical device cybersecurity risks. Original source
National Institute of Standards and Technology. (2018). Securing wireless infusion pumps in healthcare delivery organizations: Approach, architecture, and security characteristics (NIST SP 1800-8B). doi:10.6028/NIST.SP.1800-8. Original source
Therapeutic Goods Administration. (2025). Complying with medical device cyber security requirements. Australian Government. Originally published July 1, 2019; updated October 2, 2025. Original source
U.S. Department of Health and Human Services. (n.d.). Breach Notification Rule. Office for Civil Rights. Retrieved November 18, 2026. Original source
U.S. Government Accountability Office. (2023, December 21). Medical device cybersecurity: Agencies need to update agreement to ensure effective coordination (GAO-24-106683). Original source
U.S. Government Accountability Office. (2024, July 24). Medical devices: FDA has begun building an active postmarket surveillance system (GAO-24-106699). Public release August 15, 2024. Original source
United States Congress. (2022). Ensuring cybersecurity of devices, Federal Food, Drug, and Cosmetic Act section 524B, 21 U.S.C. section 360n-2 (2023 U.S. Code edition). Pub. L. 117-328, div. FF, title III, section 3305. Original source